Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Drummoyne, Australia Clinical Trials

A listing of Drummoyne, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (500) clinical trials

Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort

This study will investigate whether switching symptomatic COPD patients from a fixed-dose combination of salmeterol/fluticasone 50/500 g b.i.d. to a fixed dose combination of QVA149 110/50 g o.d. leads to improved lung function and airflow. It will also assess the effect on symptom burden, breathlessness, and use of rescue medication ...

Phase

0.09 miles

Learn More »

Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)

The purpose of this research is to determine whether giving severely injured adults a drug called tranexamic acid (TXA) as soon as possible after injury will improve their chances of survival and their level of recovery at six months. After severe injury, a person may have uncontrolled bleeding that places ...

Phase

1.43 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials will have the option to enroll in this trial to receive study medication for up to 5 years or until marketed approval

Phase

1.67 miles

Learn More »

Breathlessness Exertion and Morphine Sulphate

Background: Three hundred thousand (300,000) Australians are breathless at rest or on minimal exertion, often for years, despite optimal treatment of the underlying cause(s). This includes more than 70,000 people who are too breathless to leave their homes often for long periods of time. Underlying causes for such severe and ...

Phase

2.21 miles

Learn More »

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study will be conducted in two parts. Phase 1b is dose escalation in which patients are tested with SD-101 at various doses in combination with 200 mg pembrolizumab in patients with metastatic melanoma. Phase 2 will consist of 7 expansion cohorts to evaluate the efficacy and safety of SD-101 ...

Phase

2.54 miles

Learn More »

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A*0201 positive adult patients with advanced UM treated in the first line setting with no prior systemic or liver-directed chemo-, radio- or immune-therapy administered in the advanced ...

Phase

2.54 miles

Learn More »

Neoadjuvant Dabrafenib Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

The new drug options for advanced melanoma include oncogene-targeted therapy (such as dabrafenib, trametinib and vemurafenib) and immune checkpoint blockade (such as pembrolizumab, nivolumab and ipilimumab). These drugs have shown remarkable efficacy and have regulatory approval for metastatic disease. However, most patients with advanced disease eventually progress. It is unknown ...

Phase

2.54 miles

Learn More »

Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder

The main purpose of this study is to assess efficacy and safety of ACT-541468 in subjects with insomnia disorder. Efficacy will be evaluated on sleep onset and sleep maintenance.

Phase

2.56 miles

Learn More »

Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Study to assess the long term safety and tolerability of ACT-541468 in adult and elderly subjects suffering from difficulties to sleep

Phase

2.56 miles

Learn More »

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

The trial is a randomised, double-blind, placebo-controlled multicentre clinical trial investigating efficacy and safety of inhaled molgramostim (rhGM-CSF) in autoimmune pulmonary alveolar proteinosis (aPAP) patients. The primary objective is efficacy on the Alveolar-arterial oxygen difference after 24-weeks treatment. Secondary objectives are tolerance to exercise, effect on Quality of Life, time ...

Phase

2.83 miles

Learn More »